. 2020 May 6;S1878-8750(20)30945-1.
doi: 10.1016/j.wneu.2020.04.235.
Online ahead of print.
Affiliations
Free PMC article
Item in Clipboard
et al.
World Neurosurg.
.
Free PMC article
Abstract
We present a case of symptomatic heterotopic bone formation following revision of posterolateral lumbar fusion/instrumentation and “off-label” use of recombinant human bone morphogenetic protein-2, treated successfully with the use of a minimally invasive tubular approach.
Keywords:
Ectopic bone formation; Heterotopic bone formation; Minimally invasive surgery; rhBMP-2.
Copyright © 2020 Elsevier Inc. All rights reserved.
Similar articles
-
Symptomatic ectopic bone formation after off-label use of recombinant human bone morphogenetic protein-2 in transforaminal lumbar interbody fusion.
J Neurosurg Spine. 2010 Jan;12(1):40-6. doi: 10.3171/2009.4.SPINE0876.
J Neurosurg Spine. 2010.
PMID: 20043763 -
Complications of rhBMP-2 utilization for posterolateral lumbar fusions requiring reoperation: a single practice, retrospective case series report.
Spine J. 2013 Oct;13(10):1244-52. doi: 10.1016/j.spinee.2013.06.022. Epub 2013 Aug 22.
Spine J. 2013.
PMID: 23973099 -
Heterotopic ossification associated with recombinant human bone morphogenetic protein-2 (infuse) in posterolateral lumbar spine fusion: a case report.
Spine (Phila Pa 1976). 2012 Apr 15;37(8):E502-6. doi: 10.1097/BRS.0b013e318238870b.
Spine (Phila Pa 1976). 2012.
PMID: 22020605 -
Off-label innovation: characterization through a case study of rhBMP-2 for spinal fusion.
J Neurosurg Spine. 2016 Sep;25(3):406-14. doi: 10.3171/2016.1.SPINE151192. Epub 2016 Apr 22.
J Neurosurg Spine. 2016.
PMID: 27104282Review.
-
A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned.
Spine J. 2011 Jun;11(6):471-91. doi: 10.1016/j.spinee.2011.04.023.
Spine J. 2011.
PMID: 21729796Review.